ArticleCardio-oncology (London, England)2026
Association of sleep disturbance during breast cancer treatment and left ventricular ejection fraction decline: a prospective cohort study.
Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Sleep disturbances during breast cancer (BC) treatment may represent a modifiable contributor to left ventricular ejection fraction (LVEF) decline during BC treatment. We investigated the association of sleep disturbance and LVEF decline in a prospective cohort of 247 women with non-metastatic BC scheduled for chemotherapy as part of the UPBEAT study conducted through the Wake Forest NCI Community Oncology Research Program Research Base (WF NCORP RB; WF-97415, UG1CA189824). Participants completed cardiac magnetic resonance imaging to measure LVEF, six-minute walk distance, and validated surveys assessing sleep disturbance, physical health, and mental health at baseline and 3 months. Sleep disturbance was measured using the Patient Reported Outcomes Measurement Information System Sleep Disturbance survey. At 3-month follow-up, 30.3% of participants experienced a clinically meaningful increase in sleep disturbance, with a mean LVEF decline of -4.13%-points compared to -1.93%-points in those without increased disturbance (p = 0.10). In multivariable models adjusting for baseline risk factors and concurrent changes in health, a 10-point increase in sleep disturbance was associated with a 1.31%-point reduction in LVEF (β= -0.131; 95% CI: -0.24,-0.02; p = 0.02). Associations were robust across sensitivity analyses. This study provides evidence linking sleep disturbance during BC treatment to early LVEF decline, suggesting sleep disturbance may contribute to subclinical cardiac dysfunction independent of general health decline. Longitudinal studies incorporating objective sleep measures are warranted to clarify mechanisms and evaluate whether behavioral interventions targeting sleep could mitigate cardiovascular risk in BC survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.